KEYTRUDAź (pembrolizumab) receives new draft recommendation from NICE in U.K.
Merck announced the National Institute for Health and Care Excellence of the U.K. has issued a draft recommendation, in the form of a Final Appraisal Determination, recommending KEYTRUDAź (pembrolizumab) as a first-line treatment option for adults with advanced melanoma. October 09, 2015